earnings
confidence high
sentiment positive
materiality 0.70
Adaptive Biotechnologies reports preliminary Q4/FY2025 revenue growth of 51%/55% YoY
Adaptive Biotechnologies Corp
2025-FY EPS reported
-$0.39
revenue$276,976,000
- Total revenue FY2025 ~$277M (+55% YoY); Q4 ~$72M (+51% YoY).
- MRD revenue FY2025 ~$212M (+46% YoY); excluding milestone revenue grew 45%.
- clonoSEQ test volume FY2025 ~105,600 tests (+39% YoY); Q4 ~30,000 tests (+43% YoY).
- Cash, cash equivalents and marketable securities ~$227M as of Dec 31, 2025.
- Company expects full FY2025 net loss to decrease vs 2024; complete results due Feb 2026.